Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APVO452
- Development stage
- Preclinical
- Lead developer
- Aptevo Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
APVO452 is a trispecific immune cell engager biologic developed by Aptevo Therapeutics utilizing its proprietary ADAPTIR-FLEX™ platform. It is engineered to target prostate cancer by simultaneously binding to Prostate-Specific Membrane Antigen (PSMA) on tumor cells, CD3 on T cells to activate them, and CD40 to modulate immunosuppressive cells within the tumor microenvironment. This multi-pronged mechanism aims to achieve potent and durable anti-tumor responses while minimizing systemic toxicity.
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD40 (Cluster of differentiation 40 receptor)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on APVO452.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APVO452.